Cargando…

Treatment Options for Troublesome Itch

Itch (or pruritus) is an unpleasant sensation, inducing the desire to scratch. It is also a major and distressing symptom of many skin and systemic diseases. The involvement of histamine, which is a major itch mediator, has been extensively examined. Recent studies suggest that histamine-independent...

Descripción completa

Detalles Bibliográficos
Autores principales: Toyama, Sumika, Tominaga, Mitsutoshi, Takamori, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412524/
https://www.ncbi.nlm.nih.gov/pubmed/36015170
http://dx.doi.org/10.3390/ph15081022
_version_ 1784775515322712064
author Toyama, Sumika
Tominaga, Mitsutoshi
Takamori, Kenji
author_facet Toyama, Sumika
Tominaga, Mitsutoshi
Takamori, Kenji
author_sort Toyama, Sumika
collection PubMed
description Itch (or pruritus) is an unpleasant sensation, inducing the desire to scratch. It is also a major and distressing symptom of many skin and systemic diseases. The involvement of histamine, which is a major itch mediator, has been extensively examined. Recent studies suggest that histamine-independent pathways may play roles in chronic itch. Therefore, antihistamines are not always effective in the treatment of patients with chronic itch. The development of biologics and κ-opioid receptor (KOR) agonists has contributed to advances in the treatment of itch; however, since biologics are expensive for patients to purchase, some patients may limit or discontinue their use of these agents. Furthermore, KOR agonists need to be prescribed with caution due to risks of side effects in the central nervous system. Janus kinase (JAK) inhibitors are sometimes associated with side effects, such as infection. In this review, we summarize antidepressants, antineuralgics, cyclosporine A, antibiotics, crotamiton, phosphodiesterase 4 inhibitor, botulinum toxin type A, herbal medicines, phototherapy, and acupuncture therapy as itch treatment options other than antihistamines, biologics, opioids, and JAK inhibitors; we also explain their underlying mechanisms of action.
format Online
Article
Text
id pubmed-9412524
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94125242022-08-27 Treatment Options for Troublesome Itch Toyama, Sumika Tominaga, Mitsutoshi Takamori, Kenji Pharmaceuticals (Basel) Review Itch (or pruritus) is an unpleasant sensation, inducing the desire to scratch. It is also a major and distressing symptom of many skin and systemic diseases. The involvement of histamine, which is a major itch mediator, has been extensively examined. Recent studies suggest that histamine-independent pathways may play roles in chronic itch. Therefore, antihistamines are not always effective in the treatment of patients with chronic itch. The development of biologics and κ-opioid receptor (KOR) agonists has contributed to advances in the treatment of itch; however, since biologics are expensive for patients to purchase, some patients may limit or discontinue their use of these agents. Furthermore, KOR agonists need to be prescribed with caution due to risks of side effects in the central nervous system. Janus kinase (JAK) inhibitors are sometimes associated with side effects, such as infection. In this review, we summarize antidepressants, antineuralgics, cyclosporine A, antibiotics, crotamiton, phosphodiesterase 4 inhibitor, botulinum toxin type A, herbal medicines, phototherapy, and acupuncture therapy as itch treatment options other than antihistamines, biologics, opioids, and JAK inhibitors; we also explain their underlying mechanisms of action. MDPI 2022-08-19 /pmc/articles/PMC9412524/ /pubmed/36015170 http://dx.doi.org/10.3390/ph15081022 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Toyama, Sumika
Tominaga, Mitsutoshi
Takamori, Kenji
Treatment Options for Troublesome Itch
title Treatment Options for Troublesome Itch
title_full Treatment Options for Troublesome Itch
title_fullStr Treatment Options for Troublesome Itch
title_full_unstemmed Treatment Options for Troublesome Itch
title_short Treatment Options for Troublesome Itch
title_sort treatment options for troublesome itch
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412524/
https://www.ncbi.nlm.nih.gov/pubmed/36015170
http://dx.doi.org/10.3390/ph15081022
work_keys_str_mv AT toyamasumika treatmentoptionsfortroublesomeitch
AT tominagamitsutoshi treatmentoptionsfortroublesomeitch
AT takamorikenji treatmentoptionsfortroublesomeitch